Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5165 |
Name | uterine corpus sarcoma |
Definition | An uterine corpus cancer that is located_in the muscles of the uterus or located_in other tissues that support the uterus. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer uterine corpus cancer uterine corpus sarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN loss | AT13148 | uterine corpus sarcoma | sensitive | detail... |
RET fusion | Selpercatinib | uterine corpus sarcoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00954174 | Phase III | Carboplatin + Paclitaxel Ifosfamide + Paclitaxel | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer | Unknown status | USA | 1 |
NCT01979393 | Phase II | Cabozantinib | IRCI Gynae Sarcomas, High Grade Uterine Sarcoma | Active, not recruiting | NLD | ITA | GBR | FRA | ESP | 0 |
NCT03192059 | Phase II | Aspirin + Cyclophosphamide + Pembrolizumab + Vitamin D | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer (PRIMMO) | Completed | BEL | 0 |
NCT03926936 | Phase II | Fulvestrant | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) | Completed | NLD | BEL | 0 |
NCT05515575 | Phase II | Niraparib | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA | Active, not recruiting | USA | 0 |